Cortometrajes de vídeo

Wherever possible all patients with prostate cancer should undergo both germinal and somatic BRCA mutation testing as they represent predictive biomarkers of greater sensitivity to treatment with PARP inhibitors.

There are no randomized clinical trials addressing the continued use of Trastuzumab for Her2 positive MBC patients in prolonged remission and has become important and relevant clinical question.

Tissue-agnostic treatment based on shared genetic aberrations have provided a new direction in cancer treatment. Emerging clinical evidence indicates that many molecular aberrations can be common across tumor types with different site of origin.

For relapsed and refractory multiple myeloma, use of pomalidomide often in combination with dexamethasone or other agents is recommended in patients who have failed at least two prior treatments, including lenalidomide and a proteasome inhibitor.

Several studies carried out by institutions of repute have shown that Dasatinib 50 mg is as effective as 100 mg with less side effects.

Need to maximise the response to hypomethylating agents: Standard of care for high-risk Myelodysplastic Syndromes is Hypomethylating agents. Average time to response is about 3 months with either Azacytidine or Decitabine.

Average at diagnosis of prostate cancer is ~65 years & patients usually have multiple co- morbidities and may be on treatment with multiple prescribed medications.

Whole Genome Sequencing (Short)
Whole Genome Sequencing is new tool for precision medicine in metastatic castration

Purpose of molecular testing is to subclassify the gliomas and identify novel targets for pharmacological interventions.

In patients with renal impairment primary goal is improvement of Renal Function which is associated with improved treatment outcomes. 50% of patients present renal impairment and renal impairment is severe in 15% of patients.